Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK15 soft capsule in hemodialysis patients with secondary hyperparathyroidism
CTR20210806Phase 2Active
- Sponsor
- Shanghai Xinkai Pharmaceutical Chemical
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CK15 in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD), sponsored by Shanghai Xinkai Pharmaceutical Chemical. Started Apr 2021; status: active.
02
Drugs
CK15
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20210806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210806.